Warp. I also think their partnership estimate is on the conservative side for 2017. Their estimate for launch is 2-4 years which is a cable guy timing estimate. This is the type of product the FDA fast tracks and gets to patients very fast. If P2 results are good - look out. I am thinking the 2 year estimate is possible which brings partnership closer in my opinion.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links